News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Onconova Therapeutics Inc. Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes


5/10/2012 11:45:44 AM

NEWTOWN, Pa. & PENNINGTON, N.J.--(BUSINESS WIRE)--Onconova Therapeutics, Inc., announced today the advancement of the oral formulation of rigosertib (Estybon®, ON 01910.Na), an anti-cancer agent with demonstrated activity in solid tumors and hematologic malignancies, into a new Phase II study. The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the U.S. and EU.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES